Minze Health, a Belgium-based health tech startup pioneering digital health solutions in the field of urology, has secured $5.3 million to advance prescription digital therapeutics (PDTs) for urinary dysfunction patients.
Co-founded in 2015 by Gilles Tas, Josef Sageder, and Jiri Vermeulen, the company is known for its digital health system focusing on pelvic health, continence care, and urology. Its platform helps urologists diagnose, treat, and monitor patients with lower urinary tract symptoms (LUT).
The round was spearheaded by White Fund, with the participation of Flemish investment company PMV, Capricorn Digital Growth Fund, imec.istart future fund, marking a significant turning point in the company’s growth and expansion efforts.
Manze Health will use the new capital investment to advance its Prescription Digital Therapeutics (PDTs) to market. In its initial phase, the company plans to expand its platform and services to France and Germany while focusing on launching in the US market with its innovative at-home diagnostic solutions.
In preparation for US market entry, Minze Health has appointed Drew Moore as Vice President of Marketing and Sales. This will allow the company to sell its Homeflow and Diary Pod to the larger US market.
Homeflow is a non-invasive uroflowmetry system that can be safely used at home by patients with lower urinary tract symptoms (LUTS), enabling them to manage BPH, a urinary tract illness that currently affects more than 14 million men across the United States.
